Loading clinical trials...
Loading clinical trials...
Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or Without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
Conditions
Interventions
IMSA101
Immune checkpoint inhibitor
+1 more
Locations
14
United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Brigham and Women's Hospital/Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
July 7, 2023
Primary Completion Date
November 20, 2024
Completion Date
November 20, 2024
Last Updated
December 9, 2024
NCT07112170
NCT06925984
NCT04115254
NCT06813664
NCT04970693
Lead Sponsor
ImmuneSensor Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions